Clinical trial
Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes
NCT02641522
Study timeline
Study start (actual)2016-03-08Date precision: day
Registry last updated2018-11-02
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Type 1 Diabetesunresolved
Interventions
SiltuximabDRUG · verified · RxNorm: siltuximab
Sponsors & collaborators
Carla Greenbaum, MDlead sponsor
Janssen Research & Development, LLCcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02641522 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.